Abstract
Abstract
Purpose
To propose an optimized microsurgical and medical approach to reduce the risk of complications after penetrating keratoplasty (PKP) in patients with aniridia-associated keratopathy (AAK).
Methods
Retrospective observational case series of 25 PKP performed in 16 patients with AAK. Preoperative indications were endothelial decompensation and vascularized scars (68%) or graft failure (32%) due to limbal stem cell deficiency. The optimized approach included a combination of a small corneal graft size (around 7.0 mm), interrupted 10–0nylon sutures, simultaneous AMT as a patch, large bandage contact lens, temporary lateral tarsorrhaphy, postoperative autologous serum eye drops, and systemic immunosuppression. Main outcome measures included: visual acuity, transplant survival, and complications encountered during follow-up of 107 weeks on average.
Results
A complete modified keratoplasty scheme was used in 10 of 25 PKP (group 1), while at least one of the modifications was missing in the other 15 PKP (group 2). After 8 weeks of follow-up, the epithelium was closed in 23 eyes. Visual acuity improved in 19 eyes at 6 months of follow-up, and remained stable in six eyes. None of the eyes showed a decrease in visual acuity. At the last post-operative follow-up, this visual improvement persisted in 14 eyes and graft survival rate after 156 weeks (3 years) was 69% in group 1 versus 44% in group 2 (p = 0.39, log-rank test). Secondary corneal neovascularization (8%), scarring (4%), ulcer (4%), or graft rejection (8%) happened mostly in the second group which was missing at least one of the suggested modifications.
Conclusions
PKP in congenital aniridia must be considered as a high-risk keratoplasty. An optimized therapeutic approach seems to be promising in order to reduce the postoperative complication rate in these most difficult eyes.
Funder
Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Foster MC (1898) Congenital irideremia. Arch Ophthalmol 27(4):593–615
2. Käsmann-Kellner B, Seitz B (2014) Congenital aniridia or PAX6-Syndrome? Ophthalmologe 111:1144
3. Käsmann-Kellner B, Viestenz A, Seitz B (2015) Aniridia guides and aniridia syndrome (PAX6 syndrome): Dos and Don´ts in clinical care & Implementation of supra-regional “Aniridia Guides” can lessen progressive vision loss and improve comprehensive and individualized medical care. In: Parekh M, Poli B, Ferrari S, Teofil C, Ponzi D (eds) Aniridia—recent development in scientific and clinical research. Springer, Switzerland, pp 123–154
4. Lagali N, Wowra B, Fries FN et al (2020) Early phenotypic features of aniridia-associated keratopathy and association with PAX6 coding mutations. Ocul Surf 18(1):130–140
5. Jordan T, Hanson I, Zalatayev D et al (1992) The human PAX6 gene is mutated in two patients with aniridia. Nat Genet 1(5):328–332
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献